EUVIMEDEUVIMED entdecken
Editorial

The cardiovascular risk of JAK inhibitors in treating rheumatic diseases

Alexander Kwan iD, Elvina Ingrid, Matthew Jiang, Keith K T Lim

International Journal of Rheumatic Diseases · 2024

DOI: 10.1111/1756-185x.15308 ↗

Kurz gefasst

Editorial in der Zeitschrift International Journal of Rheumatic Diseases, 2024. Verfasst von Alexander Kwan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Unit, Department of Medicine, The University of Melbourne, Western Health, Footscray Hospital, Footscray, Victoria, Australia. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Heart Disease Risk Factors, Janus Kinase Inhibitors, Rheumatic Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

traditional cardiovascular risk factors in patients with rheumatic disease. A threshold effect may exist where mainly older patients with cardiovascular risk factors or smoking history experience a higher cardiovascular risk with JAKi use. 30 Since randomized controlled studies investigating the cardiovascular risk of JAKi are time consuming and expensive, future cohort studies and post-marketing data analyses are perhaps better suited for assessing JAKi cardiovascular risk. These should stratify patients into subgroups according to cardiovascular risk, cardiometabolic parameters, and other characteristics (such as smoking history) to determine when the benefit of JAKi use is outweighed by the risk of MACE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesHeart Disease Risk FactorsJanus Kinase InhibitorsRheumatic DiseasesHumansAntirheumatic AgentsRisk AssessmentRisk FactorsTreatment Outcome

Stichwörter der Autor:innen

JAK inhibitorbaricitinibcardiovascular riskinflammatory arthritistofacitinibupadacitinib

Substanzen

Antirheumatic AgentsJanus Kinase Inhibitors

Autor:innen und Institutionen

  • Rheumatology Unit, Department of Medicine, The University of Melbourne, Western Health, Footscray Hospital, Footscray, Victoria, Australia.

ORCID-Profile: Alexander Kwan

Zitieren

APA

Kwan, A., Ingrid, E., Jiang, M., & Lim, K. K. T. (2024). The cardiovascular risk of JAK inhibitors in treating rheumatic diseases. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.15308

Vancouver

Kwan A, Ingrid E, Jiang M, Lim KKT. The cardiovascular risk of JAK inhibitors in treating rheumatic diseases. International Journal of Rheumatic Diseases. 2024. doi:10.1111/1756-185x.15308

BibTeX
@article{Kwan2024,
  author = {Kwan, Alexander and Ingrid, Elvina and Jiang, Matthew and Lim, Keith K T},
  title = {The cardiovascular risk of JAK inhibitors in treating rheumatic diseases},
  journal = {International Journal of Rheumatic Diseases},
  year = {2024},
  doi = {10.1111/1756-185x.15308}
}
Kostenlos starten →